1stOncology™: Cancer Intelligence Service – Page 15650 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Heat Biologics to Present at the 2018 BIO Investor Forum

On October 10, 2018 Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that the company is scheduled to present at the 2018 BIO Investor Forum Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that the company is scheduled to present at the 2018 BIO Investor Forum. The Forum will be held on October 17th and 18th at the Westin St. Francis Hotel in San Francisco, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Jeff Wolf, Founder and Chief Executive Officer of Heat Biologics, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the forum.

Presentation Date: Wednesday, October 17, 2018
Time: 3:45 PM, PT
Location: Elizabethan A Room

. The Forum will be held on October 17th and 18th at the Westin St. Francis Hotel in San Francisco, California.

Presentation Date: Wednesday, October 17, 2018
Time: 3:45 PM, PT
Location: Elizabethan A Room

Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors

On October 10, 2018 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that new data relating to its molecule WP1122 will be presented at the upcoming Society for Neuro-Oncology Annual Scientific Meeting (Press release, Moleculin, OCT 10, 2018, View Source [SID1234529841]).

"We continue to make progress in the development of our inhibitor of glycolysis, WP1122," commented Dr. Donald Picker, Moleculin’s Chief Science Officer. "We believe that we have discovered new data during our IND-enabling research with animals that confirms a highly beneficial metabolism of WP1122 and significant organ accumulation of the inhibitor of glycolysis in the brain and also in the pancreas. This is especially significant because both brain and pancreatic tumors are highly dependent upon glucose for survival and WP1122 appears to have the ability to inhibit glycolysis, the process by which these tumors convert glucose into energy."

Walter Klemp, Moleculin’s Chairman and CEO added, "Metabolic inhibition of tumors is conceptually a very important approach, and we believe we have a clear translational focus. We have been pushing hard to prepare WP1122 for Investigational New Drug (IND) status. It is encouraging to have discoveries during this process that appear to confirm the initial premise and give us more hope that WP1122 could become an important new way to deal with difficult cancers like glioblastoma and pancreatic cancer."

The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. Now in its twenty fourth year, the Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults. This year’s Annual Scientific Meeting will be held November 15 – 18, 2018 at the Marriott Hotel in New Orleans, Louisiana.

Onconova Therapeutics To Present Update At The 2018 BIO Investor Forum In San Francisco

On October 10, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), reported that the Company will be presenting at the BIO Investor Forum, October 17-18, 2018, at the Westin St. Francis Hotel in San Francisco (Press release, Onconova, OCT 10, 2018, View Source [SID1234529839]). Ramesh Kumar, CEO, will present at the conference and meet with investors.

Presentation details
Date/Time: Thursday, October 18th at 11:00 AM
Venue: The Westin St. Francis, San Francisco
Presenter: Ramesh Kumar, CEO

Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018

On October 10, 2018 Horizon Pharma plc (Nasdaq: HZNP) reported that its third-quarter financial results will be released on Wednesday, Nov. 7, 2018 (Press release, Horizon Pharma, OCT 10, 2018, View Source [SID1234529838]). Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast and replay may be accessed at View Source Please connect to the Company’s website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants

On October 10, 2018 Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, reported the closing of its previously announced underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant (Press release, Histogenics, OCT 10, 2018, View Source;p=RssLanding&cat=news&id=2371122 [SID1234529836]). The net proceeds to Histogenics from this offering are approximately $15.4 million, after deducting underwriting discounts and commissions, and estimated offering expenses payable by Histogenics.

Canaccord Genuity LLC and BTIG, LLC acted as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as the co-manager for the offering. CIM Securities, LLC acted as a financial advisor to Histogenics in connection with the offering.

A shelf registration statement on Form S-3 (File No. 333-216741) relating to the public offering of the shares of common stock and the accompanying warrants to purchase shares of common stock described above was filed with the Securities and Exchange Commission (the SEC) and declared effective by the SEC on March 30, 2017. A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering are on file with the SEC and available on the SEC’s web site at www.sec.gov and can also be obtained by contacting Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at [email protected], or BTIG, LLC, 825 Third Avenue, 32nd Floor, New York, NY, 10022, or by telephone at (212) 593-7555 or by e-mail at [email protected].